<DOC>
	<DOCNO>NCT00004063</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Hyperthermia therapy kill tumor cell heat several degree body temperature . Combining hyperthermia chemotherapy interferon alfa may kill tumor cell . PURPOSE : This phase I/II trial study side effect cisplatin , gemcitabine , interferon alfa , whole-body hyperthermia well work treat patient metastatic , recurrent , refractory cancer .</brief_summary>
	<brief_title>Cisplatin , Gemcitabine , Interferon Alfa , Hyperthermia Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity tumor response patient metastatic , recurrent , refractory malignancy treat cisplatin , gemcitabine , interferon alfa , long-duration , low temperature whole body hyperthermia ( LL-WBH ) . OUTLINE : This dose escalation study cisplatin . - Phase I II : Patients receive gemcitabine IV 30 minute day 1 8 . Patients receive cisplatin IV 6 hour day 15 , follow subcutaneous interferon alfa day 16 17 . Patients undergo long-duration , low temperature whole body hyperthermia 6 hour plus gemcitabine 30 minute day 17 . Courses repeat every 5 week absence disease progression unacceptable toxicity . - Phase I : Cohorts 3-6 patient receive escalate dos cisplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose limit toxicity . The MTD cisplatin use phase II study . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic , recurrent , refractory carcinoma Measurable disease CT , MRI , physical examination No brain metastasis CNS disorder PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 90,000/mm^3 Bone marrow cellularity normal bone marrow biopsy No coagulopathy disorder Hepatic : Bilirubin great 2.0 mg/dL SGOT great 2 time upper limit normal PT le 14 second PTT le 35 second No inadequate liver function ( great 20 % involvement ) Renal : Creatinine great 1.8 mg/dL Creatinine clearance least 45 mL/min BUN great 25 mg/dL Cardiovascular : Adequate cardiac function document history , physical exam , stress exercise test ( MUGA ECHO ) rest blood pressure heart rate increase appropriately exercise LVEF least 45 % No prior myocardial infarction No symptomatic coronary artery disease No angina No significant arrhythmia No uncontrolled hypertension No thromboembolic disease Pulmonary : FEV_1 least 70 % predict Arterial PO_2 least 60 mmHg room air No massive ( great 30 % involvement ) lung disease DLCO great 50 % predict Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No seizure disorder No significant emotional instability No history malignant hyperthermia follow general anesthesia No concurrent medical illness would prevent compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : At least 6 day since major thoracic abdominal surgery Other : No concurrent cardiac glycoside , antiangina drug , arrhythmia drug , anticoagulant , thrombolytic agent , adrenal corticosteroid , aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>